e.iyer
TL2 · Córdoba
Contributes reviews on supplier material. Based in Córdoba.
Joined 26 August 2025 · last posted 4d
90 posts, newest first. Showing up to 150.
-
Seven-day rolling means and why weekly readings mislead Replied, post #99 · Outcomes › Progress reports · 24 Jul 2026 · 26 likes Measurement noise: day-to-day body mass varies by more than a kilogram on hydration, glycogen, and gut contents alone. A weekly reading is a single noisy sample of a…
-
Follow-up: Prior authorisation: what the criteria usually require Replied, post #93 · Access › Insurance & coverage · 24 Jul 2026 · 23 likes Where a criterion requires documented prior attempts, the documentation has to exist in the record rather than in your memory of it. Worth one more sentence than it…
-
Journal club: what we got wrong in an earlier session Replied, post #104 · Evidence › Journal club · 21 Jul 2026 · 0 likes The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping.
-
Historical amylin analogues and what happened to them Replied, post #33 · Compounds › Cagrilintide & amylin analogues · 18 Jul 2026 · 0 likes I read post #31 twice before replying, because I had assumed the opposite. Native amylin has awkward physical properties — it aggregates readily, which is why a stable…
-
Distinguishing a red flag from an inconvenience — a second dataset Replied, post #2 · Sourcing › Red flags · 17 Jul 2026 · 5 likes Filing a mild objection to the consensus on Distinguishing a red flag. Mild because I might be wrong; an objection because nobody has addressed the case that does not…
-
Coming back to: Batch date after test date, and other internal inconsistencies Replied, post #11 · Analytics › COA interpretation · 13 Jul 2026 · 26 likes I read post #7 twice before replying, because I had assumed the opposite. Counterpoint on Batch date, offered without confidence: the same observation is consistent…
-
Endotoxin and why it is a separate question from purity — what changed since Replied, post #75 · Analytics › Impurities & related substances · 12 Jul 2026 · 0 likes Post #74 describes the usual case. This is about the unusual one. That last point is the ceiling on what any purity figure can claim. A method that cannot see a species…
-
Which categories are strict and which are relaxed, honestly Replied, post #3 · Start Here › Welcome · 9 Jul 2026 · 9 likes This settles it for me, at least until somebody posts a reason it should not.
-
NHS criteria and how they are applied in practice Replied, post #21 · Regional › UK & Ireland · 6 Jul 2026 · 0 likes Answering the question post #19 raises rather than the one it answers. I have three months of notes on NHS criteria and the honest summary is that the trend is real and…
-
Coming back to: Reconciling a supplier certificate with an independent result Replied, post #21 · Sourcing › Vendor reports · 3 Jul 2026 · 2 likes Adding a null result on Reconciling a supplier certificate. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
-
GLP-1 receptor distribution: central and peripheral Replied, post #81 · Pharmacology › Receptor biology · 1 Jul 2026 · 0 likes Adding the measurement that post #80 says would settle it. Glucagon receptor agonism: glucagon receptor agonism increases energy expenditure and promotes hepatic fat…
-
Athletes in weight-category sports: a different risk calculus Replied, post #9 · Clinical › Special populations · 1 Jul 2026 · 3 likes On post #7 — agreed on the reasoning, with one qualification. Being outside the studied population does not mean a treatment is unsafe. It means the usual evidence is…
-
Prescription requirements and telehealth models — a second dataset Replied, post #78 · Sourcing › Regulatory · 24 Jun 2026 · 6 likes Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.
-
Micronutrient adequacy at low total intake Replied, post #23 · Nutrition & Training › Protein & intake · 7 Jun 2026 · 4 likes Post #20 put the caveat in the right place and I want to underline it. The claim about micronutrient adequacy upthread is stronger than its source supports. I have read…
-
Revisiting: The best-written scientific paper you have read Replied, post #16 · Lounge › Off topic · 5 Jun 2026 · 7 likes The claim about best-written scientific paper upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says…
-
Peak-to-trough ratio at steady state for a weekly agent — the long version Replied, post #17 · Pharmacology › Pharmacokinetics · 4 Jun 2026 · 5 likes That is the distinction I keep failing to hold on to. Written down now.
-
Moderation log format change Replied, post #57 · Meta › Announcements · 29 May 2026 · 13 likes Where I part company with post #53, and it is a narrow parting. Practical question on the rollout: will it be visible that a topic was created before or after the…
-
Publication patterns in the BPC-157 literature, examined Replied, post #3 · Compounds › Repair & healing peptides · 26 May 2026 · 24 likes Filing a mild objection to the consensus on publication patterns. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
-
Revisiting: Journal club: SURMOUNT-1, read without the press release Replied, post #48 · Evidence › Journal club · 21 May 2026 · 0 likes My position on SURMOUNT-1 is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
-
Reflectance and photometric devices: precision in practice — a second dataset Replied, post #27 · Analytics › Home & field testing · 12 May 2026 · 30 likes Since Reflectance and photometric devices keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone…
-
Coming back to: Time to steady state after a dose increase Replied, post #48 · Pharmacology › Pharmacokinetics · 7 May 2026 · 0 likes Steady state is approached in roughly four to five half-lives. For a compound with a week-long half-life that is four to five weeks, which is where the escalation…
-
Subgroup analyses: pre-specified versus discovered — a second dataset Replied, post #63 · Evidence › Trials · 28 Apr 2026 · 24 likes The arithmetic in post #61 is right; the assumption feeding it is the part to check. Adding a null result on Subgroup analyses. I looked, carefully, and found nothing,…
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #40 · Evidence › Preprints · 27 Apr 2026 · 9 likes Post #39 is the version of this I will quote in future. One addition. Version numbers on a preprint server matter. Citing version one of something now on version four…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #9 · Evidence › Journal club · 26 Apr 2026 · 0 likes The most useful reply I ever got about STEP 1 was a request to state my units. It sounds like pedantry and it has saved me twice.
-
Forced degradation studies: designing one that is informative Replied, post #43 · Analytics › Method validation · 24 Apr 2026 · 22 likes Confirming post #40 from a second method, which matters more than confirming it from a second person. What I would tell a new member reading about forced degradation…
-
Historical amylin analogues and what happened to them Replied, post #2 · Compounds › Cagrilintide & amylin analogues · 21 Apr 2026 · 23 likes Where I part company with the opening post, and it is a narrow parting. Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family…
-
List price versus negotiated price versus what you pay Replied, post #81 · Access › Pricing · 15 Apr 2026 · 3 likes Distinguishing three things in the list price versus negotiated price discussion that keep getting used interchangeably: the observation, the proposed mechanism, and…
-
Grapefruit: why this class is not the class that cares Replied, post #103 · Practice › Interactions · 31 Mar 2026 · 11 likes Reading rather than contributing, but this is the most useful thread I have found on it.
-
Second pass at: Sleep apnoea improving and the equipment implications Replied, post #4 · Wellbeing › Sleep · 26 Mar 2026 · 31 likes Where I part company with the opening post, and it is a narrow parting. Fatigue during the day and poor sleep at night are different problems with different causes and…
-
Bioimpedance and hydration: why the number moves Replied, post #22 · Outcomes › Body composition · 25 Mar 2026 · 16 likes Useful. I had the fact and not the reason, which turns out to be the important half.
-
Second pass at: Adsorptive losses at low concentration, and why dilute solutions are… Replied, post #68 · Practice › Storage & stability · 19 Mar 2026 · 0 likes Post #66 and I disagree about the size of the effect, not about the direction. Adding what did not work for me on Adsorptive losses, since the failures never get…
-
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #106 · Access › Pricing · 4 Mar 2026 · 3 likes Post #102 describes the usual case. This is about the unusual one. A cheaper option that arrives slowly has a cost in the form of running out, and people rarely price…
-
Second pass at: Robustness: the parameters worth deliberately varying Replied, post #52 · Analytics › Method validation · 28 Feb 2026 · 4 likes Robustness looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
-
Adducts: sodium, potassium, and the peak you did not expect — does this still hold? Replied, post #34 · Analytics › Mass spectrometry · 11 Feb 2026 · 0 likes Resolution and mass accuracy are different specifications. An instrument can resolve two species and still assign their masses imprecisely, and the reverse is also…
-
Trifluoroacetate content and its consequences Replied, post #85 · Analytics › Impurities & related substances · 5 Feb 2026 · 0 likes Trifluoroacetate is a counter-ion rather than an impurity, and it appears in the mass balance rather than in the chromatogram. Conflating the two accounts for several…
-
Managing an unplanned gap in supply Replied, post #12 · Access › Shortages · 23 Jan 2026 · 15 likes Answering the question post #10 raises rather than the one it answers. Where a manufacturer publishes a supply statement, that document is more reliable than any…
-
Interpreting a result that disagrees with the supplier's certificate Replied, post #89 · Sourcing › Independent verification · 21 Jan 2026 · 0 likes That matches what I have seen, for whatever a single anecdote is worth.
-
The headache that turns out to be dehydration Replied, post #126 · Nutrition & Training › Hydration & electrolytes · 6 Jan 2026 · 0 likes Marking my uncertainty on headache explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past…
-
Citation sweep results: how many references did not say what was claimed Replied, post #22 · Meta › Wiki maintenance · 26 Dec 2025 · 1 like That matches how I use it. The general statement is what you check afterwards, not what you arrive for.
-
DXA precision and the least significant change for lean mass Replied, post #81 · Outcomes › Body composition · 18 Dec 2025 · 11 likes The arithmetic in post #80 is right; the assumption feeding it is the part to check. What I would check first on DXA precision is whether the thing being measured moved…
-
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #79 · Compounds › Tirzepatide · 11 Dec 2025 · 1 like Where I part company with post #77, and it is a narrow parting. Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth…
-
Tracking that stops updating and then resumes Replied, post #52 · Sourcing › Logistics · 2 Dec 2025 · 0 likes Split shipments reduce single-point risk and increase the number of transits. Which trade is right depends on what you are protecting against.
-
Anxiety in the first weeks: drug, situation, or both — what changed since Replied, post #51 · Wellbeing › Mental health · 17 Nov 2025 · 0 likes Nothing to add on the substance. Thank you for taking the question at face value.
-
Availability by country, dated, with primary sources Replied, post #62 · Access › International · 16 Nov 2025 · 23 likes Answering the question post #58 raises rather than the one it answers. Source for the availability figure, since it was asked for. It is in the discussion rather than…
-
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Replied, post #69 · Compounds › Tirzepatide · 14 Nov 2025 · 0 likes Everything in post #65 holds. The case it does not cover is the one I have. Research-use-only tirzepatide is not approved for human use and is not made to…
-
LOD and LOQ: definitions people get wrong Started this topic · Analytics › Method validation · 12 Nov 2025 · 2 likes LOD and LOQ: definitions people get wrong — setting out what I have, and where I think it stops being reliable. What changes if the standard account of LOD and LOQ is…
-
The headache that turns out to be dehydration Replied, post #35 · Nutrition & Training › Hydration & electrolytes · 26 Oct 2025 · 14 likes Post #32 is right about the mechanism and I think understates the practical bit. Rapid correction of a genuine abnormality can be more dangerous than the abnormality,…
-
A comparison of home results against a laboratory result on the same vial Replied, post #53 · Analytics › Home & field testing · 23 Oct 2025 · 4 likes Where home testing is genuinely valuable is as a screen before spending on independent analysis, not as a substitute for it. If it helps: the failure mode here is…
-
How the vendor documentation pages are maintained, and by whom — what changed since Replied, post #73 · Sourcing › Vendor reports · 14 Oct 2025 · 16 likes I read post #69 twice before replying, because I had assumed the opposite. What "verified" means on our pages: specific lots were independently measured on stated dates…
-
Why "any advice?" is the least effective ending for a post — the long version Replied, post #65 · Start Here › How to Ask · 6 Oct 2025 · 23 likes This is the sort of exchange that makes the archive worth searching.
-
Citing a preprint in a maintained document: our rule and its reasoning — does this still… Replied, post #48 · Evidence › Preprints · 29 Sep 2025 · 14 likes Distinguishing three things in the Citing a preprint discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation…
-
Trial registration and comparing the protocol with the paper Replied, post #40 · Evidence › Trials · 21 Sep 2025 · 22 likes I read post #36 twice before replying, because I had assumed the opposite. Safety findings from a trial powered for efficacy are underpowered by construction. Absence…
-
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Replied, post #38 · Compounds › Oral incretins · 14 Sep 2025 · 5 likes Post #36 put the caveat in the right place and I want to underline it. The absorption enhancer in the licensed oral product works by transiently raising local gastric…
-
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #71 · Compounds › Retatrutide · 30 Aug 2025 · 4 likes Everything in post #67 holds. The case it does not cover is the one I have. Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote —…
-
A preprint whose numbers changed substantially at publication Replied, post #35 · Evidence › Preprints · 30 Aug 2025 · 32 likes If you cite a preprint in a maintained document here, the convention is to label it in the sentence and to note the check date. The document review will catch the update.
-
Freeze-thaw and why one cycle is not the same as five — a second dataset Replied, post #25 · Practice › Storage & stability · 12 Aug 2025 · 0 likes Visible particulate is a strong signal in the other direction: it is a reason to stop and ask rather than to filter and proceed.
-
Coming back to: Resolution and tailing factor: real acceptance criteria Replied, post #30 · Analytics › HPLC & UHPLC · 8 Aug 2025 · 0 likes Where I part company with post #28, and it is a narrow parting. System suitability testing: injections run before and during the sample run to establish whether the…
-
What a 2 ppm match establishes, and what it does not Replied, post #40 · Analytics › Mass spectrometry · 8 Aug 2025 · 1 like Adding the measurement that post #36 says would settle it. The useful distinction on 2 ppm match is between what was measured and what was inferred from it. Both end up…
-
A ten-fold dose error caught before injection — one year on Replied, post #144 · Devices › Syringes & needles · 5 Aug 2025 · 23 likes Thank you — that answers what I came here to find out.
-
Second pass at: A history of disordered eating: proceeding carefully Replied, post #91 · Wellbeing › Mental health · 17 Jul 2025 · 0 likes Everything in post #88 holds. The case it does not cover is the one I have. Speaking only to history of disordered eating as I have actually seen it, rather than as it…
-
Sequence verification for an obscure compound: how it is done Replied, post #87 · Compounds › Other compounds · 9 Jul 2025 · 16 likes Post #83 and I disagree about the size of the effect, not about the direction. Practical note on sequence verification: write down what you expect before you look. The…
-
A report I filed that turned out to be wrong, and the correction Replied, post #70 · Sourcing › Vendor reports · 25 May 2025 · 1 like Post #69 is right about the mechanism and I think understates the practical bit. The cost of a submission is worth stating. It is the main reason people do not do this…
-
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #117 · Sourcing › Independent verification · 19 May 2025 · 0 likes I would rather this thread reach "we do not know" about Janoshik than reach a confident answer that nobody can support when asked.
-
Asking about a compound your prescriber has not heard of Replied, post #22 · Clinical › Prescriber conversations · 22 Apr 2025 · 20 likes Bringing a record of symptoms with dates and severities makes an assessment materially easier and is the single most useful preparation.
-
Reading a trial's population section before its results — does this still hold? Replied, post #25 · Evidence › Trials · 20 Apr 2025 · 6 likes A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened…
-
Review: a draft on reconstitution arithmetic, with objections Replied, post #104 · Documentation › Doc review · 13 Apr 2025 · 0 likes Review the scope as well as the content. A page attempting too much is the commonest structural problem at this stage. This is the version I would want a new member to…
-
Requesting a translation of an existing page Replied, post #5 · Documentation › Wiki requests · 29 Mar 2025 · 6 likes I had read the opposite somewhere and cannot now find where, which tells me something.
-
Follow-up: Open-label extensions: what survives and what does not Replied, post #18 · Evidence › Trials · 25 Mar 2025 · 6 likes Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment),…
-
An appeal that failed, and what I would do differently Started this topic · Access › Insurance & coverage · 21 Mar 2025 · 4 likes An appeal that failed, and what I would do differently Writing it up because I had to work it out twice and would rather nobody else did. Asking about appeal directly,…
-
Validating a method you did not develop — does this still hold? Replied, post #94 · Analytics › Method validation · 10 Mar 2025 · 0 likes Forced degradation studies: deliberately stress the material with acid, base, oxidant, heat, light to generate degradation products and demonstrate that the method can…
-
Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #82 · Access › International · 6 Mar 2025 · 21 likes I have been on both sides of the Cross-border purchase within argument in this category within eighteen months, which should tell you how strong the evidence for either…
-
Validating a method you did not develop — does this still hold? Replied, post #75 · Analytics › Method validation · 5 Mar 2025 · 32 likes Post #72 answers the question as asked. The question underneath it is different. Checked the Validating a method claim against the primary source this morning. It…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #40 · Practice › Reconstitution · 24 Feb 2025 · 14 likes Dead volume is the part nobody mentions until it costs them a dose. A fixed-needle insulin syringe holds very little; a detachable-needle luer configuration can hold…
-
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #68 · Evidence › Meta-analyses · 7 Feb 2025 · 0 likes Fixed-effect and random-effects models answer different questions. The first assumes one true effect; the second assumes a distribution of them. Choosing between them…
-
Telehealth prescribing models in the US Replied, post #47 · Regional › North America · 18 Jan 2025 · 0 likes Coming back to post #43, because the follow-up matters more than the original answer. Telehealth prescribing: widespread in the US and varying in quality. Models…
-
Body image changing more slowly than the body Replied, post #47 · Wellbeing › Mental health · 16 Dec 2024 · 20 likes I read post #45 twice before replying, because I had assumed the opposite. Something worth flagging about body image: the strongest-sounding claims in this thread are…
-
Asking about a compound your prescriber has not heard of — one year on Replied, post #7 · Clinical › Prescriber conversations · 23 Nov 2024 · 14 likes Post #5 is right about the mechanism and I think understates the practical bit. Clarifying indication: if a compound is approved for diabetes but you have obesity…
-
SURPASS-2 and the comparator dose question that will not go away Replied, post #57 · Compounds › Tirzepatide · 16 Nov 2024 · 11 likes Building on post #56 rather than restating it. Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive…
-
Journal club: SURMOUNT-1, read without the press release Replied, post #12 · Evidence › Journal club · 9 Nov 2024 · 0 likes Post #8 put the caveat in the right place and I want to underline it. Counterpoint on SURMOUNT-1, offered without confidence: the same observation is consistent with a…
-
Follow-up: Oral contraceptives and delayed emptying: what the data shows Replied, post #22 · Practice › Interactions · 28 Oct 2024 · 11 likes Thyroid medications: semaglutide is associated with a slowing of gastric emptying, which might affect thyroid medication absorption if they are taken very close…
-
Second pass at: Hoarding and why it makes a shortage worse Replied, post #32 · Access › Shortages · 10 Oct 2024 · 0 likes Anyone reporting availability should say the region and the date, because both determine whether the report is usable.
-
Irish differences from the UK position Replied, post #24 · Regional › UK & Ireland · 6 Oct 2024 · 6 likes Practical note on irish differences: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would…
-
Reading a supplementary appendix and finding the interesting part Replied, post #2 · Evidence › Trials · 3 Oct 2024 · 14 likes Confirming the opening post from a second method, which matters more than confirming it from a second person. Two sentences on reading a supplementary appendix and then…
-
Patterns that reliably precede a problem, documented Replied, post #2 · Sourcing › Red flags · 19 Sep 2024 · 0 likes Nothing to add on the substance. Thank you for taking the question at face value.
-
Reporting a discrepancy without making an allegation Replied, post #55 · Sourcing › Vendor reports · 3 Sep 2024 · 0 likes Worth separating two things that post #51 runs together. Adding the boring version of reporting a discrepancy, because the interesting version keeps getting posted and…
-
Correlation in a self-tracked dataset: what it can support Replied, post #112 · Research Methods › Statistics · 24 Aug 2024 · 4 likes Confirming post #111 from a second method, which matters more than confirming it from a second person. Survivorship in a self-reporting population biases every…
-
Pen wastage and its effect on real cost Replied, post #14 · Access › Pricing · 8 Aug 2024 · 0 likes The practical version of pen wastage is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
-
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #14 · Analytics › COA interpretation · 27 Jul 2024 · 6 likes A certificate is a statement by its issuer that a defined test was performed on a defined lot and produced a defined result. That is all it is, and it is not nothing.
-
Second pass at: Journal club: LEADER as the historical anchor Replied, post #68 · Evidence › Journal club · 26 Jul 2024 · 11 likes Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
-
Cold packs, phase-change material, and what survives ten days Replied, post #39 · Sourcing › Logistics · 24 Jun 2024 · 28 likes Thank you for taking the time. That was more work than a reply usually is.